ad image

Ophthalmology

1 / 1
The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success
Ophthalmology

The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success

Tracey Roberts, MSHS; Jennifer Christiansen, Ph.D.; Debra Schaumberg, Sc.D., O.D., M.P.H.

PPD, part of Thermo Fisher Scientific

PAO-08-24-CL-05Sep 16, 2024
Pioneering Breakthroughs in Retinal Disease Treatment
Retinal Disease

Pioneering Breakthroughs in Retinal Disease Treatment

David Alvaro, Ph.D.; David Zacks, M.D., Ph.D.; David Esposito

Pharma's Almanac

PAO-12-23-CL-01Dec 14, 2023
Transformative Early and Patient-Centric Treatments for Retinal Diseases
Ophthalmic

Transformative Early and Patient-Centric Treatments for Retinal Diseases

David Alvaro, Ph.D.; Kerrie Brady

Pharma's Almanac

PAO-05-022-CL-06May 17, 2022
Hovione
Global License Agreement

Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

Hovione

PR-M05-22-04May 09, 2022
On the Future of Ocular Therapies
Ophthalmology

On the Future of Ocular Therapies

Roca Therapeutics

PAO-04-22-R221-63Apr 29, 2021
Hovione
Ophthalmology

Hovione Completes its Phase II Clinical Trial of the First Minocycline Ophthalmic Showing Promise in Dry Eye Disease Associated with Inflamed Meibomian Gland Dysfunction

Hovione

PR-M03-21-003Mar 17, 2021
Targeting Retinal Diseases with an Ophthalmic Formulation of Bevacizumab
Ophthalmic Formulation

Targeting Retinal Diseases with an Ophthalmic Formulation of Bevacizumab

Larry Kenyon

Outlook Therapeutics

PAP-Q4-20-CL-018Dec 09, 2020
Tackling Genetic Eye Diseases with Novel RNA Therapies
Ophthalmology

Tackling Genetic Eye Diseases with Novel RNA Therapies

Daniel A. de Boer

ProQR Therapeutics

PAP-Q4-19-CL-027Dec 06, 2019
Innovative Therapies to Treat Rare and Underserved Eye Diseases
Ophthalmology

Innovative Therapies to Treat Rare and Underserved Eye Diseases

Shankar Musunuri, Ph.D.

Ocugen

PAP-Q4-19-CL-025Dec 06, 2019
Aldeyra Therapeutics

Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision

Aldeyra Therapeutics

PR-M01-19-NI-096Feb 01, 2019
1 / 1